topotecan has been researched along with px 478 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garber, K | 1 |
| Belozerov, VE; Van Meir, EG | 1 |
| Qing, L; Qing, W | 1 |
1 review(s) available for topotecan and px 478
| Article | Year |
|---|---|
Hypoxia inducible factor-1: a novel target for cancer therapy.
Topics: Benzopyrans; Cell Hypoxia; Heterocyclic Compounds, 4 or More Rings; Humans; Hypoxia-Inducible Factor 1; Microtubules; Models, Biological; Mustard Compounds; Neoplasms; Phenylpropionates; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Sirolimus; Topotecan; Tubulin Modulators | 2005 |
2 other study(ies) available for topotecan and px 478
| Article | Year |
|---|---|
New drugs target hypoxia response in tumors.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; DNA-Binding Proteins; Drugs, Investigational; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mustard Compounds; Neoplasms; Neovascularization, Pathologic; Nuclear Proteins; Phenylpropionates; Topotecan; Transcription Factors; Transplantation, Heterologous | 2005 |
Hypoxia inducible factor 1 inhibitors for cancer therapy.
Topics: Antineoplastic Agents; Camptothecin; Digoxin; Flavonoids; Humans; Hypoxia-Inducible Factor 1; Mustard Compounds; Neoplasms; Oligonucleotides; Phenylpropionates; Polyethylene Glycols; Topotecan | 2019 |